Save time and jump to the most important pieces.
SC 13D/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
SC 13D - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
SC 13D/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)
Chardan Capital resumed coverage of La Jolla Pharmaceutical with a rating of Buy and set a new price target of $15.00
15-12G - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)
S-8 POS - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)
S-8 POS - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)
Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $42 million in July 2022 Entered into definitive merger agreement to acquire all outstanding shares of La Jolla Pharmaceutical Company for $6.23 per share in cash at an implied enterprise value of $149 million in July 2022 Sold 15% economic stake in Theravance Respiratory Company ("TRC") to Royalty Pharma for approximately $282 million and a potential $50 million milestone payment plus full ownership of existing equity investments TRC previou
Acquisition to strengthen Innoviva's infectious disease and hospital portfolio with addition of GIAPREZA® and XERAVA® Innoviva, Inc. (NASDAQ:INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla. Innoviva has agreed to pay $5.95 per share for La Jolla, representing a premium of approximately 70% to the 30-day volume-
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2022 and highlighted corporate progress. Corporate Progress Net Product Sales: For the three months ended March 31, 2022, La Jolla's net product sales were $10.4 million, up 21% from the same period in 2021. GIAPREZA U.S. Net Product Sales: For the three months ended March 31, 2022, GIAPREZA U.S. net product sales were $7.7 million, up 13% from the same period in 2021. XERAVA U.S. Net Product Sales: For the three months ended
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Tony Hodges, M.D., FACP, FCCP, as Chief Medical Officer. "We are thrilled to have Tony join our team here at La Jolla," said Larry Edwards, President and Chief Executive Officer of La Jolla. "Tony's clinical experience, operational leadership and in-depth knowledge of critical care medicine are key to helping La Jolla grow net sales of GIAPREZA and XERAVA and become a leader in the critical care space." "I look forward to working with the La Jolla team to continue to
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) ("La Jolla") at a price of $6.23 per share (the "Offer Price"), net to the seller in cash, without interest and less required withholding taxes, expired one minute after 11:59 p.m. New York City time on Friday, August 19, 2022. Today, following the consummation of the tender offer, Innoviva successfully completed its acquisition of La Jolla, which is dedicated to the commercializa
Gainers Kaspien Holdings Inc. (NASDAQ:KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media. Pliant Therapeutics, Inc. (NASDAQ:PLRX) shares surged 159% to close at $23.00 on Monday after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study. La Jolla Pharmaceutical Company (NASDAQ:LJPC) climbed 81% to close at $6.14 after Innoviva entered into a definitive agreement to acquire the company for $5.95 per share and an incremental $0.28 per share for additional cash proceeds, or an implied enterprise value of approximately $149 million. Iterum Therapeutics plc (NASDAQ:ITRM) gained
U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June. The Dow traded down 0.30% to 31,242.86 while the NASDAQ fell 1.85% to 11,419.99. The S&P also fell, dropping, 0.92% to 3,863.48. Also check this: GameStop, Levi Strauss And 3 Stocks To Watch Heading Into Friday Leading and Lagging Sectors Utilities shares rose by 0.3% on Monday. Meanwhile, top gainers in the sector included Enel Chile SA - ADR (NYSE:ENIC), up 3% and UGI Corp (NYSE:UGI) up 2%. In trading on Monday, communication services shares dipped by 2.6%. Top Headline AZZ Inc (NYSE:AZZ) reported better-than-expected earnings for its first quarter on Monday.
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) ("La Jolla") at a price of $6.23 per share (the "Offer Price"), net to the seller in cash, without interest and less required withholding taxes, expired one minute after 11:59 p.m. New York City time on Friday, August 19, 2022. Today, following the consummation of the tender offer, Innoviva successfully completed its acquisition of La Jolla, which is dedicated to the commercializ
Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $42 million in July 2022 Entered into definitive merger agreement to acquire all outstanding shares of La Jolla Pharmaceutical Company for $6.23 per share in cash at an implied enterprise value of $149 million in July 2022 Sold 15% economic stake in Theravance Respiratory Company ("TRC") to Royalty Pharma for approximately $282 million and a potential $50 million milestone payment plus full ownership of existing equity investments TRC previou
Acquisition to strengthen Innoviva's infectious disease and hospital portfolio with addition of GIAPREZA® and XERAVA® Innoviva, Inc. (NASDAQ:INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla. Innoviva has agreed to pay $5.95 per share for La Jolla, representing a premium of approximately 70% to the 30-day volume-